EX-10.17
from 10QSB
~10
pages
This Executive Services Agreement (“Agreement”) Is Made Effective the 28th Day of June, 2006. Jointly Between: Chemokine Therapeutics Corp. and Chemokine Therapeutics (Bc) Corp. 6190 Agronomy Road, Vancouver, Bc. Canada V6t 1z3 (“Company”) and Guy Ely, MD, (“Executive”) N.D. Life Sciences Corporation 2372 Valley Forest Way Oakville, Ontario Canada L6h 6w9 Executive Services Agreement
12/34/56
EX-10.22
from S-B/A
3 pages
April 12, 2005 David Karp Chief Financial Officer Chemokine Therapeutics Corp. 2386 East Mall – Suite 208 Vancouver, Bc V6t 1z3 Canada via Campus Mail Dear Mr. Karp, Re: Amendment to License Agreement Between Ubc and Chemokine Therapeutics Corporation Dated September 22, 1999 (The “License”). This Letter Agreement Is to Amend the Subject of the License. the Parties Hereby Agree to Amend the License by Making the Following Changes: 1. Change Section 11.4(c) So That It Shall Now Read: (C) Commence Phase II Clinical Trials by December 31, 2005. the Licensee Covenants to Notify the University, in Writing, Within 15 Days of the Commencement of Phase II Clinical Trials;” 2. Change Section 12.2 So That It Shall Now Read: 12.2 the Licensee Will Complete and Deliver to Ubc
12/34/56